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Abstract
Obesity is a worldwide pandemic representing one of the major challenges that societies face around the globe.
Identifying the mechanisms involved in its development and propagation will help the development of
preventative and therapeutic strategies that may help control its rising rates.
Obesity is associated with chronic low-grade inflammation, and this is believed to be one of the major contributors
to the development of insulin resistance, which is an early event in obesity and leads to type 2 diabetes when the
pancreas fails to keep up with increased demand for insulin. In this review, we discuss the role of macrophages in
mediation of inflammation in obesity in metabolic organs including adipose tissue, skeletal muscle and liver. The
presence of immune cells at the interface with metabolic organs modulates both metabolic function and
inflammatory responses in these organs, and may provide a potential therapeutic target to modulate metabolic
function in obesity.
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Introduction
More than one billion people around the world are
overweight or obese, and one in eight of those is a child
[1]. Another worldwide pandemic is type 2 diabetes,
with around 350 million people affected[2] and this is
mostly related to obesity. The burdens of obesity and
diabetes with their co-morbidities on the individual,
family, community, health care systems, and society at
large is one of the biggest challenges that societies face
around the globe[3]. Understanding the mechanisms
involved in the development of the two conditions paves
the way for design of preventative and therapeutic stra-
tegies that may stem their progress.
I nt h i sr e v i e w ,w eh i g h l i g h tt h er o l eo ft h em a c r o -
phage, an immune cell, in the development of obesity-
mediated inflammation. We review the evidence for
the intersection of nutrient and cytokine sensing in
immune and metabolic organs, and assess the evidence
for presence and actions of macrophages in metabolic
organs.
Nutrient sensing, cytokine signaling and inflammation in
obesity
It is well established that obesity is associated with
inflammation[4-15], but this inflammation is different
from that seen in infection or autoimmunity. First, obe-
sity-associated inflammation does not fulfill the usual
description of acute inflammation with redness, heat,
swelling, and pain but follows a more chronic and low-
grade course[16-19]. Second, inflammation in obesity is
a systemic process that affects many organs, but may
begin in one or more organs. Inflammation starts in adi-
pose tissue as it expands with excess fat and caloric
intake, and involves activation of inflammatory pathways
in cells by nutrient-sensing and cytokine signaling.
Nutrient sensing occur via pattern recognition receptors
including membrane-based innate immune receptors
known as toll-like receptors 2 and 4 (TLR2 & TLR4),
and intracellular pathogen sensing NOD-like receptors
[20-24]. These receptors were originally thought to be
involved only in pathogen sensing, but recently were
found to sense fatty acids.
In addition, cytokines are produced in response to
inflammatory stimuli from different organs, and can
act in an autocrine, paracrine or endocrine fashion
[25-30]. Fatty acids and cytokines converge to activate
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activation of these pathways leads to production of
transcription factors that enter the nucleus and acti-
vate inflammatory cytokine gene expression and cyto-
kine production, leading to propagation of
inflammation[31-34](Figure 1).
Recently, an intriguing mechanism was proposed as
an explanation for obesity. CNS deletion of Toll-like
receptor 4(TLR4) adaptor MyD88 protected mice
from high fat diet-mediated obesity. Intracerebroven-
tricular administration of saturated fatty acid palmi-
tate did not elicit leptin or insulin resistance and did
not increase hypothalamic inflammatory cytokines.
This indicates that high fat diet in part acts centrally
even before meaningful weight gain to trigger leptin
and insulin resistance. This leads to dysregulation of
anorexigenic effects of leptin and insulin, and initia-
tion and progression of obesity[35]. Hypothalamic
inflammation as a starting point for obesity is an
interesting mechanism that requires further study
[36,37].
Immune cells in metabolic organs drive inflammation in
obesity
While many mechanisms leading to inflammation in
obesity are not completely understood, it is clear that
the interaction between immune and metabolic cells
initiates and propagates the inflammatory response.
Adipose tissue expansion in obesity outpaces its blood
supply, resulting in adipose tissue hypoxia and activation
of inflammatory responses, with production of factors
including Hypoxia Inducible Factor-1a [HIF-1a][38]. It
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Figure 1 Fatty acids and cytokines utilize similar downstream signaling pathways to activate inflammatory response in obesity.
Saturated fatty acids signal via toll-like receptors (TLRs), and cytokines signal via respective cytokine receptors (CR) to activate MAPK enzymes
including JNK, ERK, and p38MAPK along with IB and protein kinase C (PKC) pathways. Other mechanisms include activation of these pathways
by NOD-like receptors (NLRs), production of reactive oxygen species and oxidative stress, and endoplasmic reticulum stress (ER stress). The
activation of these pathways leads to production of transcription factors including NFB and C-Jun that enter nucleus and bind specific
sequences on gene promoters, and lead to transcription of inflammatory cytokine and chemokine genes. The cytokines produced will act in an
autocrine, paracrine and endocrine manner and interfere with insulin signaling. They will also stimulate further cytokine production that will
propagate the activation of these pathways, leading to further inflammation.
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enhanced production of leptin and resistin, and reduced
production of adiponectin [39-50].
In addition, inflammation results in secretion of cyto-
kines and chemokines. This will activate adipose tissue
T- lymphocytes and resident macrophages, which are
present in adipose tissue under physiological conditions.
This then leads to secretion of pro-inflammatory cyto-
kines and chemokines from these cells that attract
immune cells including other T-lymphocytes, neutro-
phils, and monocytes[16,18,51-60]. Once in adipose tis-
sue, monocytes differentiate to macrophages, and start
secreting cytokines that propagate local inflammation in
adipose tissue.
Inflammatory pathway activation drives
inflammation and insulin resistance in obesity
Inflammation mediated by increased cytokine produc-
tion and excess fatty acids or ‘lipotoxicity’ activate
inflammatory pathways in immune and metabolic cells.
These pathways include Mitogen Activated Protein
Kinase (MAPK) pathway members including c-jun
amino terminal kinase (JNK), Extracellular Regulated
Kinase (ERK), and p38MAPK. In addition IBk i n a s e
[61-69] and protein kinase C (PKC)[70-73] pathways are
also activated. The activation of these pathways leads to
interference with insulin signaling leading to insulin
resistance, an early event in obesity[16,53-57]. Insulin
resistance leads to mitigation of anti-lipolytic effect of
insulin on adipose tissue, and lipolysis ensues with local
fatty acid release triggering further local inflammation.
What begins as a local process eventually exceed the
capacity of adipose tissue to contain it, and cytokines
and free fatty acids are released into the circulation and
reach metabolic organs including skeletal muscle and
liver[74,75].
In skeletal muscle, this is compounded by the pre-
sence of Intermyocellular Fat Depot [IMFD] that
expands with obesity and harbors immune cells includ-
ing macrophages[76](Figure 2).
In addition, fatty acid uptake into muscle cells leads to
accumulation of intracellular triglycerides, which act as a
sink to protect muscle from lipotoxicity. Interestingly,
athletes have excess triglyceride stores in skeletal muscle,
but demonstrate enhanced insulin sensitivity. This ‘ath-
lete’s paradox’ hints to the fact that triglycerides are not
the culprits in mediating inflammation and insulin resis-
tance, but it is metabolic intermediates like ceramide and
diacylglycerol generated intracellularly that interfere with
insulin signaling and trigger inflammation[77-79].
The deposition of fat into the liver leads to fatty liver
with activation of inflammatory pathways, secretion of
inflammatory cytokines, monocyte attraction and
macrophage generation, which in turn leads to hepatic
inflammation and insulin resistance [32,80].
The initial response to compensate for insulin resis-
tance is via increased insulin production by pancreatic
b-islet cells, leading to hyperinsulinemia. Eventually, the
pancreas fails to maintain insulin production in the face
of steadily increasing insulin demand, leading to the
development of type 2 diabetes.
Inflammation is associated with macrophage infiltration
of metabolic organs
The detection of enhanced expression of Tumor Necro-
sis Factor-a [TNF- a], a prototypical inflammatory cyto-
kine, in adipose tissue in obese mice provided first clues
to presence of inflammation in obesity[81]. This was
then confirmed in obese and diabetic humans[4]. The
source of TNF-a was initially presumed to be the adipo-
cyte, but it was eventually found to be from an immune
cell, the macrophage[16,18,82-85]. These cells produce
multiple cytokines and chemokines in obesity that mod-
ulate function of metabolic organs leading to inflamma-
tion and insulin resistance[83-85].
Macrophages are mononuclear phagocytic cells that
are part of the innate immune system, an evolutionarily
conserved defense system with cells placed at ports of
entry of pathogens and other environmental threats to
the body[86-88]. One function for these cells is sampling
antigens as they enter the body and then either destroy
them by an ‘innate response’ with no memory kept of
the encounter, or present the antigen to the T-lympho-
cytes to mount an adaptive immune response[27,86].
The precursors of macrophages, the monocytes, are gen-
erated in the bone marrow. These cells are recruited to
adipose tissue by signals from adipocytes and adipose
tissue macrophages[89,90]. Once in the adipose tissue,
the monocytes differentiate to macrophages[91].
Phenotypic characterization of macrophages in
metabolic organs
Adipose tissue
Early in obesity, adipocytes are predominantly responsi-
ble for producing chemokines and macrophages are
involved in producing cytokines, but both cells are cap-
able of producing these molecules, and can modulate
function of metabolic organs leading to inflammation
and insulin resistance[83-85]. Adipose tissue macro-
phages are present in two main subtypes. The resident
or ‘M2’ macrophages are present in almost all organs in
the body as resident cells under physiological conditions,
where they serve to maintain tissue homeostasis[92-95].
Under normal physiological states, 5-10% of adipose tis-
sue cells are resident M2 macrophages. These cells are
distinguished by being responsive to IL-4 and IL-13 and
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IL-10.
In addition, M2 macrophages upregulate production
of Arginase I enzyme, reducing nitric oxide synthesis
and inflammation via metabolizing arginine to ornithine
[92,93,96-100]. Arginase I gene expression is stimulated
by IL-4 and Signal Transducer and Activator of Tran-
scription-6 (STAT-6) axis[101]. This in turn signals via
the master regulator of adipogenesis and fatty acid sen-
sor Peroxisome Proliferator-Activated Receptor gamma
(PPARg).
PPAR/RXR heterodimers bind to specific sequences at
the Arginase I gene enhancer region activating its
expression[102]. PPARg is essential for attainment and
preservation of M2 macrophage phenotype, as its dele-
tion in macrophages leads to excess adiposity in mice
on high fat diet. It also results in insulin resistance in
skeletal muscle and liver in these mice. When adipo-
cytes are co-incubated with PPARg knockout macro-
phages, they become insulin resistant, which argues for
factors produced by these macrophages, including IL-4
among others, that modulate metabolic function in adi-
pose tissue, liver and skeletal muscle[102,103].
On the other hand, bone marrow-derived monocytes
migrating into obese adipose tissue and exposed to fatty
acids and cytokines differentiate to an inflammatory or
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Figure 2 The model for macrophage-metabolic interactions and inflammation in obesity. Adipose tissue expansion in obesity results in an
inflammatory state characterized by production of adipokines, cytokines, and chemokines. This is also associated with free fatty acid [FFA] release
via increased lipolysis. Activation of resident or ‘M2’ adipose tissue macrophages leads to secretion of inflammatory cytokines and chemokines;
this will lead to attraction of monocytes that differentiate to macrophages. Fatty acids and cytokines spill into circulation, and get to metabolic
tissues including skeletal muscle and liver. In addition, the expansion of the intermyocellular fat depot also attracts macrophages, and this is
associated with secretion of pro-inflammatory cytokines, chemokines and FFA release that occur locally. The exposure of muscle to cytokines,
chemokines and fatty acids from systemic and local sources triggers an inflammatory response characterized by activation of inflammatory
pathways, upregulation of gene expression, and synthesis and secretion of inflammatory cytokines and chemokines. The attracted macrophages
will in turn secrete inflammatory molecules, which signal through inflammatory pathways propagating this inflammatory response and resulting
in muscle inflammation and insulin resistance. JNK = c-jun amino terminal kinase; PKC = protein kinase C.
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responsive to interferon gamma and lipopolysaccharide,
and are capable of producing pro-inflammatory cyto-
kines and nitric oxide. Their numbers increase several
folds with obesity and high fat feeding[18].
The M1/M2 divide is a simplistic view of the reality of
macrophage existence in different organs[106,107].
Macrophages very likely exist in multiple intermediate
phenotypes depending on local tissue microenvironment
[98,99], and are able to respond to local cues and shift
their phenotype to maintain local tissue homeostasis.
Another consideration is that while M1 macrophages
in obese adipose tissue originate mainly from bone mar-
row [90], it is possible that other cells may contribute to
this pool. The pre-adipocyte may be a potential source
of macrophages in obese adipose tissue, as these cells
share common capabilities with macrophages in
response to obesogenic environments.
Pre-adipocytes reside in stromal vascular fraction
within adipose tissue, and are bathed in the same cock-
tail of nutrients and cytokines that influence their inter-
actions with other cells in that environment[108-110].
Macrophages are capable of storing lipids as seen in
foam cells present in atherosclerotic plaques, and foam-
like cells are also seen in obese adipose tissue[111-113].
Pre-adipocytes injected into peritoneal cavity of mice
can act like macrophages, with phagocytosis of microor-
ganisms and posses antimicrobial actions via generation
of reactive oxygen species [108,110]. These abilities dis-
appear when cells differentiate to mature adipocytes.
Pre-adipocytes can also differentiate to macrophages
with expression of many macrophage markers[108], and
this is probably due to direct physical contact between
pre-adipocyte and macrophage. In addition, the tran-
scriptional profile of pre-adipocyte is in fact closer to
the macrophage than to the adipocyte, and these cells
p r o d u c em a n yc o m m o np r o d u c t st ob o t hi n c l u d i n g
cytokines, chemokines, and adhesion molecules
[108,110,114,115].
More recently, weight loss in mice previously fed
high fat diet lead to infiltration of adipose tissue with
M2 macrophages. This was mediated by lipolysis, and
macrophages were acting as neutralizers of effects of
excess fat in obese adipose tissue [74]. This is in con-
trast to when weight gain leads to the infiltration of
M1 macrophages, and argues for a robust immune
response to local adipose tissue microenvironment,
and this M2 infiltration may be an attempt to protect
adipose tissue from mounting an inflammatory
response with excess local fatty acid concentrations.
The ultimate aim of inflammation is the induction of
tissue remodeling and to restore homeostasis, and M2
macrophages act to initiate and propagate this process
with weight loss[116,117], and depending on local
tissue microenvironment, there is potential plasticity in
cell phenotype.
Skeletal muscle
In skeletal muscle, circulating cytokines and fatty acids
and those produced locally from IMFD [e.g. TNFa,I L -
6] jointly affect muscle. Macrophages infiltrate IMFD
when it expands in obesity [18], and as the IMFD depot
is in immediate vicinity of skeletal muscle, it is likely
that muscle-macrophage crosstalk will impact both cells.
Insulin resistance in muscle is caused by several
mechanisms including fatty acid oxidation defects due
to effects on mitochondrial biogenesis, oxidative stress,
accumulation of lipid intermediates in muscle, and
effects of pro-inflammatory cytokine on insulin signaling
[57,61,118-122].
Macrophage products from saturated fatty acid treat-
ment in-vitro causes skeletal muscle insulin resistance
[123]. The question whether macrophages infiltrate ske-
letal muscle in obesity is important, as muscle takes up
to 75% of carbohydrate intake after a meal, making it a
major determinant of postprandial glycemic status.
There is increasing evidence that macrophages may
infiltrate skeletal muscle in obesity. In rodents, high fat
feeding increases macrophage infiltration in muscle
compared to normal chow fed animals [124]. In addi-
tion, deletion of PPARg in myeloid cells, a master regu-
lator of adipogenesis and inflammation, also resulted in
increased macrophage and dendritic cell markers in
muscle [125]. Macrophage markers have been documen-
ted mainly in IMFD, and rarely between myofibrils with
high fat feeding using immunohistochemistry [18,124]
and bone marrow transplant experiments [126]. In the
latter case, macrophages were detected at the muscle-fat
junction, raising the question of whether their location
denotes a non-directional chemokinetic response, or a
true directional, chemotactic response to factors pro-
duced by muscle.
Furthermore, dendritic cell were detected in muscle
from high fat fed mice, and fatty acid treatment of bone
marrow derived macrophages [BMDM] and dendritic
cells [BMDC] induced inflammation in the BMDC and
not BMDM [126].
In human studies, macrophages were detected in ske-
letal muscle from obese non-diabetic subjects and this
was positively associated with body mass index and
negatively associated with insulin sensitivity [127].
Macrophages were also detected in human muscle from
subjects with normal glucose tolerance but at much
lower levels than in adipose tissue [128].
However, other studies failed to demonstrate the pre-
sence of macrophage markers using microarrays of mus-
cle from high fat fed mice [16] and no increase of
macrophage markers in muscle was noted in severely
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[129].
While the above studies provide evidence for and
against the infiltration of skeletal muscle by macro-
phages, there are also challenges to pinpoint the
mechanisms of muscle-macrophage interaction in obe-
sity. First, whole tissue analysis for presence of macro-
phage markers does not necessarily clarify the location
of these macrophages, as they could be adherent to the
endothelium within blood vessel lumen rather than infil-
trating into muscle tissue when tissues are prepared for
analysis. Second, a significant challenge is to clarify if
these macrophages are in fact infiltrating within muscle
fibers or are they mainly in the IMFD that expands in
obesity and attracts macrophages. The potential
mechanisms and pathways involved in macrophage
recruitment to muscle remain incompletely understood.
Liver
The accumulation of fat in the liver causes Non-alco-
holic fatty liver disease (NAFLD) which is an important
complication of obesity[130]. Resident liver macrophages
[Kupffer cells] play a significant protective role in obe-
sity by producing anti-inflammatory cytokines e.g. IL-10,
and their depletion results in hepatic inflammation and
insulin resistance[131]. In addition, obesity leads to
macrophage recruitment to the liver via their Chemo-
kine C-C receptor-2 (CCR2) in response to Chemokine
C-C ligand-2 (CCL2) produced by hepatocytes, and
these cells regulate hepatic lipid accumulation in the
liver[132,133].
In addition, the depletion of resident liver macro-
phages [Kupffer cells] leads to protection from effects of
high fat feeding-induced inflammation.
The association of liver inflammation via the produc-
tion of inflammatory cytokines including TNFa and IL-
6 has recently been also linked to the development of
hepatocellular carcinoma via stimulation of STAT-3
[134]. As obesity is associated with risk of several can-
cers, this is a novel area of research that requires further
investigation to clarify the link between obesity, inflam-
mation and cancer.
Conclusions
In summary, obesity is associated with chronic low-
grade inflammation, and macrophage crosstalk with
metabolic organs mediates this inflammatory response.
Macrophage precursors are recruited to metabolic
organs in obesity, and produce several factors that lead
to inflammation and insulin resistance in these organs.
The Inflammatory process seen in obesity is caused by
the activation of several pathways activated by nutrients
including fatty acids and cytokines. The collusion of
these stimuli leads to interference with insulin signaling
and insulin resistance (Figure 2), which is an early step
on the path to type 2 diabetes.
Defining the mechanisms by which different pathways
and molecules modulate progression of inflammation in
obesity holds the promise of developing interventions
that may help hundreds of millions of people around
the world struggling with obesity and type 2 diabetes.
Acknowledgements
The author wishes to acknowledge research support from new investigator
fund grant from Hamilton Health Sciences, Hamilton, Ontario, Canada. The
author also acknowledges funding support from the Canadian Pediatric
Endocrine Group (CPEG).
Competing interests
The author declares that they have no competing interests.
Received: 23 July 2011 Accepted: 28 October 2011
Published: 28 October 2011
References
1. WHO Fact sheet: Obesity and overweight. [http://www.who.int/
dietphysicalactivity/publications/facts/obesity/en/], (Accessed July-12th-
2011).
2. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK,
Farzadfar F, Khang Y-H, Stevens GA, et al: National, regional, and global
trends in fasting plasma glucose and diabetes prevalence since 1980:
systematic analysis of health examination surveys and epidemiological
studies with 370 country-years and 2.7 million participants. The Lancet
2011, 378(9785):31-40.
3. Kelly T, Yang W, Chen CS, Reynolds K, He J: Global burden of obesity in
2005 and projections to 2030. Int J Obes 2008, 32(9):1431-1437.
4. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased
adipose tissue expression of tumor necrosis factor-alpha in human
obesity and insulin resistance. J Clin Invest 1995, 95(5):2409-2415.
5. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor
necrosis factor-alpha: direct role in obesity-linked insulin resistance.
Science 1993, 259(5091):87-91.
6. Schenk S, Saberi M, Olefsky JM: Insulin sensitivity: modulation by nutrients
and inflammation. J Clin Invest 2008, 118(9):2992-3002.
7. Asferg C, Jensen JS, Marott JL, Appleyard M, Mogelvang R, Jensen GB,
Jeppesen J: Markers of inflammation and hemodynamic measurements
in obesity: Copenhagen City Heart Study. Am J Hypertens 2009,
22(4):451-456.
8. Bullo M, Casas-Agustench P, Amigo-Correig P, Aranceta J, Salas-Salvado J:
Inflammation, obesity and comorbidities: the role of diet. Public Health
Nutr 2007, 10(10A):1164-1172.
9. Clement K, Vignes S: [Inflammation, adipokines and obesity]. Rev Med
Interne 2009, 30(9):824-832.
10. Ferrante AW Jr: Obesity-induced inflammation: a metabolic dialogue in
the language of inflammation. J Intern Med 2007, 262(4):408-414.
11. Greenberg AS, Obin MS: Obesity and the role of adipose tissue in
inflammation and metabolism. Am J Clin Nutr 2006, 83(2):461S-465S.
12. Hotamisligil GS: Inflammation and endoplasmic reticulum stress in
obesity and diabetes. Int J Obes (Lond) 2008, , 32 Suppl 7: S52-54.
13. Hurt RT, Frazier TH, Matheson PJ, Cave MC, Garrison RN, McClain CJ,
McClave SA: Obesity and inflammation: III. Curr Gastroenterol Rep 2007,
9(4):307-308.
14. Hurt RT, Frazier TH, Matheson PJ, Cave MC, Garrison RN, McClain CJ,
McClave SA: Obesity and inflammation: II. Curr Gastroenterol Rep 2007,
9(4):306-307.
15. Hardy OT, Perugini RA, Nicoloro SM, Gallagher-Dorval K, Puri V, Straubhaar J,
Czech MP: Body mass index-independent inflammation in omental
adipose tissue associated with insulin resistance in morbid obesity.
Surgery for Obesity and Related Diseases 2011, 7(1):60-67.
16. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A,
Ross JS, Tartaglia LA, et al: Chronic inflammation in fat plays a crucial role
Samaan Diabetology & Metabolic Syndrome 2011, 3:29
http://www.dmsjournal.com/content/3/1/29
Page 6 of 9in the development of obesity-related insulin resistance. J Clin Invest
2003, 112(12):1821-1830.
17. Neels JG, Olefsky JM: Inflamed fat: what starts the fire? J Clin Invest 2006,
116(1):33-35.
18. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr:
Obesity is associated with macrophage accumulation in adipose tissue. J
Clin Invest 2003, 112(12):1796-1808.
19. Andel M, Polak J, Kraml P, Dlouhy P, Stich V: [Chronic mild inflammation
links obesity, metabolic syndrome, atherosclerosis and diabetes]. Vnitr
Lek 2009, 55(7-8):659-665.
20. Nguyen MT, Favelyukis S, Nguyen AK, Reichart D, Scott PA, Jenn A, Liu-
Bryan R, Glass CK, Neels JG, Olefsky JM: A subpopulation of macrophages
infiltrates hypertrophic adipose tissue and is activated by free fatty acids
via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem
2007, 282(48):35279-35292.
21. Senn JJ: Toll-like Receptor-2 Is Essential for the Development of
Palmitate-induced Insulin Resistance in Myotubes. Journal of Biological
Chemistry 2006, 281(37):26865-26875.
22. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS: TLR4 links innate
immunity and fatty acid induced insulin resistance. The Journal of Clinical
Investigation 2006, 116(11):3015-3025.
23. Takeda K, Kaisho T, Akira S: Toll-like receptors. Annual Review of
Immunology 2003, 21(1):335-376.
24. Tamrakar AK, Schertzer JD, Chiu TT, Foley KP, Bilan PJ, Philpott DJ, Klip A:
NOD2 activation induces muscle cell-autonomous innate immune
responses and insulin resistance. Endocrinology 2010, 151(12):5624-5637.
25. Catalan V, Gomez-Ambrosi J, Ramirez B, Rotellar F, Pastor C, Silva C,
Rodriguez A, Gil MJ, Cienfuegos JA, Fruhbeck G: Proinflammatory
cytokines in obesity: impact of type 2 diabetes mellitus and gastric
bypass. Obes Surg 2007, 17(11):1464-1474.
26. Dinarello CA: Role of pro- and anti-inflammatory cytokines during
inflammation: experimental and clinical findings. J Biol Regul Homeost
Agents 1997, 11(3):91-103.
27. Kabelitz D, Medzhitov R: Innate immunity–cross-talk with adaptive
immunity through pattern recognition receptors and cytokines. Curr
Opin Immunol 2007, 19(1):1-3.
28. Matsuzawa Y, Shimomura I, Kihara S, Funahashi T: Importance of
adipocytokines in obesity-related diseases. Horm Res 2003, 60(Suppl
3):56-59.
29. Nishimura S, Manabe I, Nagai R: Adipose tissue inflammation in obesity
and metabolic syndrome. Discov Med 2009, 8(41):55-60.
30. Sell H, Dietze-Schroeder D, Kaiser U, Eckel J: Monocyte chemotactic
protein-1 is a potential player in the negative cross-talk between
adipose tissue and skeletal muscle. Endocrinology 2006, 147(5):2458-2467.
31. Bergman RN, Ader M: Free Fatty Acids and Pathogenesis of Type 2
Diabetes Mellitus. Trends in Endocrinology and Metabolism 2000,
11(9):351-356.
32. van Herpen NA, Schrauwen-Hinderling VB: Lipid accumulation in non-
adipose tissue and lipotoxicity. Physiol Behav 2008, 94(2):231-241.
33. Turpin SM, Ryall JG, Southgate R, Darby I, Hevener AL, Febbraio MA,
Kemp BE, Lynch GS, Watt MJ: Examination of ‘lipotoxicity’ in skeletal
muscle of high-fat fed and ob/ob mice. J Physiol 2009, 587(Pt
7):1593-1605.
34. Sell H, Eckel J: Chemotactic cytokines, obesity and type 2 diabetes: in
vivo and in vitro evidence for a possible causal correlation? Proc Nutr Soc
2009, 68(4):378-384.
35. Kleinridders A, Schenten D, Konner AC, Belgardt BF, Mauer J, Okamura T,
Wunderlich FT, Medzhitov R, Bruning JC: MyD88 signaling in the CNS is
required for development of fatty acid-induced leptin resistance and
diet-induced obesity. Cell Metab 2009, 10(4):249-259.
36. Velloso LA, Araujo EP, de Souza CT: Diet-induced inflammation of the
hypothalamus in obesity. Neuroimmunomodulation 2008, 15(3):189-193.
37. Wisse BE, Schwartz MW: Does hypothalamic inflammation cause obesity?
Cell Metab 2009, 10(4):241-242.
38. Yu J, Shi L, Wang H, Bilan PJ, Yao Z, Samaan MC, He Q, Klip A, Niu W:
Conditioned medium from hypoxia-treated adipocytes renders muscle
cells insulin resistant. Eur J Cell Biol 2011, 90(12):1000-1015.
39. Trayhurn P, Wang B, Wood IS: HIF-1alpha protein rather than mRNA as a
marker of hypoxia in adipose tissue in obesity: focus on “inflammation
is associated with a decrease of lipogenic factors in omental fat in
women,” by Poulain-Godefroy et al. Am J Physiol Regul Integr Comp Physiol
2008, 295(4):R1097, author reply R1098.
40. Ye J: Emerging Role of Adipose Tissue Hypoxia in Obesity and Insulin
Resistance. Int J Obes (Lond) 2009, 33(1):54-66.
41. Calabro P, Yeh ET: Obesity, inflammation, and vascular disease: the role
of the adipose tissue as an endocrine organ. Subcell Biochem 2007,
42:63-91.
42. Clement K, Vega N, Laville M, Pelloux V, Guy-Grand B, Basdevant A, Vidal H:
Adipose tissue gene expression in patients with a loss of function
mutation in the leptin receptor. Int J Obes Relat Metab Disord 2002,
26(12):1533-1538.
43. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM,
Hughes IA, McCamish MA, O’Rahilly S: Effects of recombinant leptin
therapy in a child with congenital leptin deficiency. N Engl J Med 1999,
341(12):879-884.
44. Farooqi IS, O’Rahilly S: Leptin: a pivotal regulator of human energy
homeostasis. Am J Clin Nutr 2009, 89(3):980S-984S.
45. Harsch IA, Bergmann T, Koebnick C, Wiedmann R, Ruderich F, Hahn EG,
Konturek PC: Adiponectin, resistin and subclinical inflammation–the
metabolic burden in Launois Bensaude Syndrome, a rare form of
obesity. J Physiol Pharmacol 2007, , 58 Suppl 1: 65-76.
46. La Cava A, Alviggi C, Matarese G: Unraveling the multiple roles of leptin
in inflammation and autoimmunity. J Mol Med 2004, 82(1):4-11.
47. Martin SS, Qasim A, Reilly MP: Leptin resistance: a possible interface of
inflammation and metabolism in obesity-related cardiovascular disease.
J Am Coll Cardiol 2008, 52(15):1201-1210.
48. McTernan PG, Fisher FM, Valsamakis G, Chetty R, Harte A, McTernan CL,
Clark PM, Smith SA, Barnett AH, Kumar S: Resistin and type 2 diabetes:
regulation of resistin expression by insulin and rosiglitazone and the
effects of recombinant resistin on lipid and glucose metabolism in
human differentiated adipocytes. J Clin Endocrinol Metab 2003,
88(12):6098-6106.
49. Trayhurn P, Wood IS: Adipokines: inflammation and the pleiotropic role
of white adipose tissue. Br J Nutr 2004, 92(3):347-355.
50. Trayhurn P, Wood IS: Signalling role of adipose tissue: adipokines and
inflammation in obesity. Biochem Soc Trans 2005, 33(Pt 5):1078-1081.
51. Elgazar-Carmon V, Rudich A, Hadad N, Levy R: Neutrophils transiently
infiltrate intra-abdominal fat early in the course of high-fat feeding. J
Lipid Res 2008, 49(9):1894-1903.
52. Takeya M: [Monocytes and macrophages–multifaced cell population
involved in inflammation, atherosclerosis, and obesity]. Nippon Rinsho
2005, 63(Suppl 4):117-122.
53. Goodpaster BH, Wolf D: Skeletal muscle lipid accumulation in obesity,
insulin resistance, and type 2 diabetes. Pediatr Diabetes 2004, 5(4):219-226.
54. Shoelson SE, Lee J, Yuan M: Inflammation and the IKK beta/I kappa B/NF-
kappa B axis in obesity- and diet-induced insulin resistance. Int J Obes
Relat Metab Disord 2003, 27(Suppl 3):S49-52.
55. Sartipy P, Loskutoff DJ: Monocyte chemoattractant protein 1 in obesity
and insulin resistance. Proc Natl Acad Sci USA 2003, 100(12):7265-7270.
56. Marette A: Molecular mechanisms of inflammation in obesity-linked
insulin resistance. Int J Obes Relat Metab Disord 2003, 27(Suppl 3):S46-48.
57. Hotamisligil GS: Inflammatory pathways and insulin action. Int J Obes
Relat Metab Disord 2003, 27(Suppl 3):S53-55.
58. Ilan Y, Maron R, Tukpah AM, Maioli TU, Murugaiyan G, Yang K, Wu HY,
Weiner HL: Induction of regulatory T cells decreases adipose
inflammation and alleviates insulin resistance in ob/ob mice. Proc Natl
Acad Sci USA 107(21):9765-9770.
59. Lumeng CN, Maillard I, Saltiel AR: T-ing up inflammation in fat. Nat Med
2009, 15(8):846-847.
60. Kintscher U, Hartge M, Hess K, Foryst-Ludwig A, Clemenz M, Wabitsch M,
Fischer-Posovszky P, Barth TF, Dragun D, Skurk T, et al: T-lymphocyte
infiltration in visceral adipose tissue: a primary event in adipose tissue
inflammation and the development of obesity-mediated insulin
resistance. Arterioscler Thromb Vasc Biol 2008, 28(7):1304-1310.
61. Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR,
Pedersen BK: Tumor Necrosis Factor-Î± Induces Skeletal Muscle Insulin
Resistance in Healthy Human Subjects via Inhibition of Akt Substrate
160 Phosphorylation. Diabetes 2005, 54(10):2939-2945.
62. Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li Jw, Young DB,
Barbosa M, Mann M, Manning A, et al: IKK-1 and IKK-2: Cytokine-Activated
Samaan Diabetology & Metabolic Syndrome 2011, 3:29
http://www.dmsjournal.com/content/3/1/29
Page 7 of 9IkB Kinases Essential for NF-kB Activation. Science 1997,
278(5339):860-866.
63. Yin MJ, Yamamoto Y, Gaynor RB: The anti-inflammatory agents aspirin
and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998,
396(6706):77-80.
64. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw-
Boris A, Poli G, Olefsky J, Karin M: IKK-beta links inflammation to obesity-
induced insulin resistance. Nat Med 2005, 11(2):191-198.
65. Vallerie SN, Furuhashi M, Fucho R, Hotamisligil GS: A predominant role for
parenchymal c-Jun amino terminal kinase (JNK) in the regulation of
systemic insulin sensitivity. PLoS One 2008, 3(9):e3151..
66. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M,
Hotamisligil GS: A central role for JNK in obesity and insulin resistance.
Nature 2002, 420(6913):333-336.
67. Aguirre V, Uchida T, Yenush L, Davis R, White MF: The c-Jun NH(2)-terminal
kinase promotes insulin resistance during association with insulin
receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 2000,
275(12):9047-9054.
68. Solinas G, Karin M: JNK1 and IKKβ: molecular links between obesity and
metabolic dysfunction. The FASEB Journal 24(8):2596-2611.
69. Hotamisligil GS: Role of endoplasmic reticulum stress and c-Jun NH2-
terminal kinase pathways in inflammation and origin of obesity and
diabetes. Diabetes 2005, 54(Suppl 2):S73-78.
70. Kim JK, Fillmore JJ, Sunshine MJ, Albrecht B, Higashimori T, Kim DW, Liu ZX,
Soos TJ, Cline GW, O’Brien WR, et al: PKC-theta knockout mice are
protected from fat-induced insulin resistance. J Clin Invest 2004,
114(6):823-827.
71. Liu YF, Paz K, Herschkovitz A, Alt A, Tennenbaum T, Sampson SR, Ohba M,
Kuroki T, LeRoith D, Zick Y: Insulin stimulates PKCzeta -mediated
phosphorylation of insulin receptor substrate-1 (IRS-1). A self-attenuated
mechanism to negatively regulate the function of IRS proteins. J Biol
Chem 2001, 276(17):14459-14465.
72. Haasch D, Berg C, Clampit JE, Pederson T, Frost L, Kroeger P,
Rondinone CM: PKCtheta is a key player in the development of insulin
resistance. Biochem Biophys Res Commun 2006, 343(2):361-368.
73. Samuel VT, Liu ZX, Wang A, Beddow SA, Geisler JG, Kahn M, Zhang XM,
Monia BP, Bhanot S, Shulman GI: Inhibition of protein kinase Cepsilon
prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J
Clin Invest 2007, 117(3):739-745.
74. Kosteli A, Sugaru E, Haemmerle G, Martin JF, Lei J, Zechner R, Ferrante AW
Jr: Weight loss and lipolysis promote a dynamic immune response in
murine adipose tissue. J Clin Invest 2010, 120(10):3466-3479.
75. Guilherme A, Virbasius JV, Puri V, Czech MP: Adipocyte dysfunctions
linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell
Biol 2008, 9(5):367-377.
76. Patsouris D, Neels JG, Fan W, Li PP, Nguyen MT, Olefsky JM:
Glucocorticoids and thiazolidinediones interfere with adipocyte-
mediated macrophage chemotaxis and recruitment. J Biol Chem 2009,
284(45):31223-31235.
77. Goodpaster BH, He J, Watkins S, Kelley DE: Skeletal Muscle Lipid Content
and Insulin Resistance: Evidence for a Paradox in Endurance-Trained
Athletes. Journal of Clinical Endocrinology & Metabolism 2001,
86(12):5755-5761.
78. van Loon LJC, Koopman R, Manders R, van der Weegen W, van
Kranenburg GP, Keizer HA: Intramyocellular lipid content in type 2
diabetes patients compared with overweight sedentary men and highly
trained endurance athletes. American Journal of Physiology - Endocrinology
And Metabolism 2004, 287(3):E558-E565.
79. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, Bergeron R, Kim JK,
Cushman SW, Cooney GJ, et al: Mechanism by Which Fatty Acids Inhibit
Insulin Activation of Insulin Receptor Substrate-1 (IRS-1)-associated
Phosphatidylinositol 3-Kinase Activity in Muscle. Journal of Biological
Chemistry 2002, 277(52):50230-50236.
80. Shulman GI: Cellular mechanisms of insulin resistance. J Clin Invest 2000,
106(2):171-176.
81. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor
necrosis factor-alpha: direct role in obesity-linked insulin resistance.
Science 1993, 259:87-91.
82. Bourlier V, Bouloumie A: Role of macrophage tissue infiltration in obesity
and insulin resistance. Diabetes Metab 2009, 35(4):251-260.
83. Bruun JM, Lihn AS, Pedersen SB, Richelsen B: Monocyte Chemoattractant
Protein-1 Release Is Higher in Visceral than Subcutaneous Human
Adipose Tissue (AT): Implication of Macrophages Resident in the AT. J
Clin Endocrinol Metab 2005, 90(4):2282-2289.
84. Chavey C, Lazennec G, Lagarrigue S, Clape C, Iankova I, Teyssier J,
Annicotte JS, Schmidt J, Mataki C, Yamamoto H, et al: CXC ligand 5 is an
adipose-tissue derived factor that links obesity to insulin resistance. Cell
Metab 2009, 9(4):339-349.
85. Lacasa D, Taleb S, Keophiphath M, Miranville A, Clement K: Macrophage-
secreted factors impair human adipogenesis: involvement of
proinflammatory state in preadipocytes. Endocrinology 2007,
148(2):868-877.
86. Janeway CA, Medzhitov R: Innate Immune Recognition. Annual Review of
Immunology 2002, 20(1):197-216.
87. Karagiannides I, Pothoulakis C: Obesity, innate immunity and gut
inflammation. Curr Opin Gastroenterol 2007, 23(6):661-666.
88. Medzhitov R: Recognition of microorganisms and activation of the
immune response. Nature 2007, 449(7164):819-826.
89. Lumeng CN, DelProposto JB, Westcott DJ, Saltiel AR: Phenotypic switching
of adipose tissue macrophages with obesity is generated by
spatiotemporal differences in macrophage subtypes. Diabetes 2008,
57(12):3239-3246.
90. Lumeng CN, Deyoung SM, Bodzin JL, Saltiel AR: Increased inflammatory
properties of adipose tissue macrophages recruited during diet-induced
obesity. Diabetes 2007, 56(1):16-23.
91. Lumeng CN, Bodzin JL, Saltiel AR: Obesity induces a phenotypic switch in
adipose tissue macrophage polarization. J Clin Invest 2007, 117(1):175-184.
92. Gordon S, Martinez FO: Alternative activation of macrophages:
mechanism and functions. Immunity 32(5):593-604.
93. Martinez FO, Helming L, Gordon S: Alternative activation of macrophages:
an immunologic functional perspective. Annu Rev Immunol 2009,
27:451-483.
94. Zeyda M, Farmer D, Todoric J, Aszmann O, Speiser M, Gyori G, Zlabinger GJ,
Stulnig TM: Human adipose tissue macrophages are of an anti-
inflammatory phenotype but capable of excessive pro-inflammatory
mediator production. Int J Obes 2007, 31(9):1420-1428.
95. Zeyda M, Stulnig TM: Adipose tissue macrophages. Immunology Letters
2007, 112(2):61-67.
96. Hume DA: The mononuclear phagocyte system. Curr Opin Immunol 2006,
18(1):49-53.
97. Hume DA: Differentiation and heterogeneity in the mononuclear
phagocyte system. Mucosal Immunol 2008, 1(6):432-441.
98. Gordon S: The macrophage: past, present and future. Eur J Immunol 2007,
37(Suppl 1):S9-17.
99. Gordon S: Macrophage heterogeneity and tissue lipids. J Clin Invest 2007,
117(1):89-93.
100. Varin A, Gordon S: Alternative activation of macrophages: immune
function and cellular biology. Immunobiology 2009, 214(7):630-641.
101. Ricardo-Gonzalez RR, Red Eagle A, Odegaard JI, Jouihan H, Morel CR,
Heredia JE, Mukundan L, Wu D, Locksley RM, Chawla A: IL-4/STAT6
immune axis regulates peripheral nutrient metabolism and insulin
sensitivity. Proc Natl Acad Sci USA 2010, 107(52):22617-22622.
102. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V,
Mukundan L, Red Eagle A, Vats D, Brombacher F, Ferrante AW, et al:
Macrophage-specific PPARgamma controls alternative activation and
improves insulin resistance. Nature 2007, 447(7148):1116-1120.
103. Odegaard JI, Chawla A: Alternative macrophage activation and
metabolism. Annu Rev Pathol 2011, 6:275-297.
104. Cybulsky MI, Lichtman AH, Hajra L, Iiyama K: Leukocyte adhesion
molecules in atherogenesis. Clin Chim Acta 1999, 286(1-2):207-218.
105. Ley K, Laudanna C, Cybulsky MI, Nourshargh S: Getting to the site of
inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol
2007, 7(9):678-689.
106. Aron-Wisnewsky J, Tordjman J, Poitou C, Darakhshan F, Hugol D,
Basdevant A, Aissat A, Guerre-Millo M, Clement K: Human adipose tissue
macrophages: m1 and m2 cell surface markers in subcutaneous and
omental depots and after weight loss. J Clin Endocrinol Metab 2009,
94(11):4619-4623.
107. Geissmann Fdr, Gordon S, Hume DA, Mowat AM, Randolph GJ: Unravelling
mononuclear phagocyte heterogeneity. Nat Rev Immunol 10(6):453-460.
Samaan Diabetology & Metabolic Syndrome 2011, 3:29
http://www.dmsjournal.com/content/3/1/29
Page 8 of 9108. Charriére G, Cousin B, Arnaud E, André M, Bacou F, Pénicaud L, Casteilla L:
Preadipocyte Conversion to Macrophage. Journal of Biological Chemistry
2003, 278(11):9850-9855.
109. Cousin B, Andre M, Casteilla L, Penicaud L: Altered macrophage-like
functions of preadipocytes in inflammation and genetic obesity. J Cell
Physiol 2001, 186(3):380-386.
110. Cousin B, Munoz O, Andre M, Fontanilles AM, Dani C, Cousin JL,
Laharrague P, Casteilla L, Penicaud L: A role for preadipocytes as
macrophage-like cells. FASEB J 1999, 13(2):305-312.
111. Aqel NM, Ball RY, Waldmann H, Mitchinson MJ: Monocytic origin of foam
cells in human atherosclerotic plaques. Atherosclerosis 1984, 53(3):265-271.
112. Palmer AM, Murphy N, Graham A: Triglyceride-rich lipoproteins inhibit
cholesterol efflux to apolipoprotein (apo) A1 from human macrophage
foam cells. Atherosclerosis 2004, 173(1):27-38.
113. Tian L, Luo N, Klein RL, Chung BH, Garvey WT, Fu Y: Adiponectin reduces
lipid accumulation in macrophage foam cells. Atherosclerosis 2009,
202(1):152-161.
114. Wellen KE, Hotamisligil GS: Obesity-induced inflammatory changes in
adipose tissue. J Clin Invest 2003, 112(12):1785-1788.
115. Wellen KE, Hotamisligil GS: Inflammation, stress, and diabetes. J Clin Invest
2005, 115(5):1111-1119.
116. de Souza CJ, Eckhardt M, Gagen K, Dong M, Chen W, Laurent D, Burkey BF:
Effects of Pioglitazone on Adipose Tissue Remodeling Within the Setting
of Obesity and Insulin Resistance. Diabetes 2001, 50(8):1863-1871.
117. Suganami T, Ogawa Y: Adipose tissue macrophages: their role in adipose
tissue remodeling. Journal of Leukocyte Biology 2010, 88(1):33-39.
118. Hotamisligil GS: Mechanisms of TNF-alpha-induced insulin resistance. Exp
Clin Endocrinol Diabetes 1999, 107(2):119-125.
119. Hotamisligil GS: Molecular mechanisms of insulin resistance and the role
of the adipocyte. Int J Obes Relat Metab Disord 2000, 24(Suppl 4):S23-27.
120. Saltiel AR, Kahn CR: Insulin signalling and the regulation of glucose and
lipid metabolism. Nature 2001, 414(6865):799-806.
121. Dietze D, Koenen M, Röhrig K, Horikoshi H, Hauner H, Eckel J: Impairment
of Insulin Signaling in Human Skeletal Muscle Cells by Co-Culture With
Human Adipocytes. Diabetes 2002, 51(8):2369-2376.
122. Holloway GP, Bonen A, Spriet LL: Regulation of skeletal muscle
mitochondrial fatty acid metabolism in lean and obese individuals. Am J
Clin Nutr 2009, 89(1):455S-462.
123. Samokhvalov V, Bilan PJ, Schertzer JD, Antonescu CN, Klip A: Palmitate-
and lipopolysaccharide-activated macrophages evoke contrasting insulin
responses in muscle cells. Am J Physiol Endocrinol Metab 2009, 296(1):
E37-46.
124. Hong E-G, Ko HJ, Cho Y-R, Kim H-J, Ma Z, Yu TY, Friedline RH, Kurt-Jones E,
Finberg R, Fischer MA, et al: Interleukin-10 Prevents Diet-Induced Insulin
Resistance by Attenuating Macrophage and Cytokine Response in
Skeletal Muscle. Diabetes 2009, 58(11):2525-2535.
125. Hevener AL, Olefsky JM, Reichart D, Nguyen MT, Bandyopadyhay G,
Leung HY, Watt MJ, Benner C, Febbraio MA, Nguyen AK, et al: Macrophage
PPAR gamma is required for normal skeletal muscle and hepatic insulin
sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest
2007, 117(6):1658-1669.
126. Patsouris D, Li PP, Thapar D, Chapman J, Olefsky JM, Neels JG: Ablation of
CD11c-positive cells normalizes insulin sensitivity in obese insulin
resistant animals. Cell Metab 2008, 8(4):301-309.
127. Varma V, Yao-Borengasser A, Rasouli N, Nolen GT, Phanavanh B, Starks T,
Gurley C, Simpson P, McGehee RE Jr, Kern PA, et al: Muscle inflammatory
response and insulin resistance: synergistic interaction between
macrophages and fatty acids leads to impaired insulin action. Am J
Physiol Endocrinol Metab 2009, 296(6):E1300-1310.
128. Di Gregorio GB, Yao-Borengasser A, Rasouli N, Varma V, Lu T, Miles LM,
Ranganathan G, Peterson CA, McGehee RE, Kern PA: Expression of CD68
and macrophage chemoattractant protein-1 genes in human adipose
and muscle tissues: association with cytokine expression, insulin
resistance, and reduction by pioglitazone. Diabetes 2005, 54(8):2305-2313.
129. Bruun JM, Helge JW, Richelsen B, Stallknecht B: Diet and exercise reduce
low-grade inflammation and macrophage infiltration in adipose tissue
but not in skeletal muscle in severely obese subjects. Am J Physiol
Endocrinol Metab 2006, 290(5):E961-967.
130. Tordjman J, Guerre-Millo M, Clement K: Adipose tissue inflammation and
liver pathology in human obesity. Diabetes Metab 2008, 34(6 Pt
2):658-663.
131. Clementi AH, Gaudy AM, van Rooijen N, Pierce RH, Mooney RA: Loss of
Kupffer cells in diet-induced obesity is associated with increased hepatic
steatosis, STAT3 signaling, and further decreases in insulin signaling.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2009,
1792(11):1062-1072.
132. Obstfeld AE, Sugaru E, Thearle M, Francisco AM, Gayet C, Ginsberg HN,
Ables EV, Ferrante AW Jr: C-C chemokine receptor 2 (CCR2) regulates the
hepatic recruitment of myeloid cells that promote obesity-induced
hepatic steatosis. Diabetes 2010, 59(4):916-925.
133. Yang S, IglayReger H, Kadouh H, Bodary P: Inhibition of the chemokine (C-
C motif) ligand 2/chemokine (C-C motif) receptor 2 pathway attenuates
hyperglycaemia and inflammation in a mouse model of hepatic
steatosis and lipoatrophy. Diabetologia 2009, 52(5):972-981.
134. Park EJ, Lee JH, Yu G-Y, He G, Ali SR, Holzer RG, ÷sterreicher CH,
Takahashi H, Karin M: Dietary and Genetic Obesity Promote Liver
Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression.
Cell 2010, 140(2):197-208.
doi:10.1186/1758-5996-3-29
Cite this article as: Samaan: The macrophage at the intersection of
immunity and metabolism in obesity. Diabetology & Metabolic Syndrome
2011 3:29.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Samaan Diabetology & Metabolic Syndrome 2011, 3:29
http://www.dmsjournal.com/content/3/1/29
Page 9 of 9